Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial ( dy of DMXAA (AS1404)combined with carb...)

Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial

dy of DMXAA (AS1404) combined with carboplatin and paclitaxel in recurrent ovarian cancer).

Background on ASA404 ASA404 (DMXAA, formerly AS1404) is a small-molecule vascular disrupting agent which targets the blood vessels that nourish tumours. The drug was discovered by Professors Bruce Baguley and William Denny and their teams at the Auckland Cancer Society Research Centre, University of Auckland, New Zealand. It was in-licensed by Antisoma from Cancer Research Ventures Limited (now Cancer Research Technology) in August 2001. Antisoma signed a worldwide development and marketing agreement for ASA404 with Novartis in April 2007.

Background on Antisoma Based in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. Antisoma fills its development pipeline by acquiring promising new product candidates from internationally recognised academic or cancer research institutions. Its core activity is the preclinical and clinical development of these drug candidates. Please visit www.antisoma.com for further information.

Page: 1 2 3
Related medicine technology :

1. Data supporting three Antisoma programmes presented at AACR
2. Antisoma plc (UK) - Second lung cancer trial adds to positive data on AS1404
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

Post Your Comments:

(Date:11/30/2009)...wswire-FirstCall/ -- Covance Inc. (NYSE: CVD ) t...affray 21st Annual Health Care Conference on Wedne...rs may access a live webcast of the presentation a...nload any necessary software, please log on 10 min...inceton, New Jersey, is one of the world,s largest...

(Date:11/30/2009)...RNewswire/ -- The Eleventh Annual Southeastern BIO... Charleston Place Hotel in the historic district o...yl Liljestrand, Dr. Harry Guttman, and Dr. Jeremy ...ill attend. SEBIO 2009 promises to bring innovati...entrepreneurs, and service providers from around t...

(Date:11/30/2009)...swire-FirstCall/ -- Henry Schein, Inc., (Nasdaq: ...ts and services, announced today that Steven Palad...ief Financial Officer, will present at the NASDAQ ...2009. The conference is taking place at the Mayfa...tion is scheduled to begin at 9:15 a.m. EST and ca...

Breaking Medicine Technology:Henry Schein to Present at the NASDAQ OMX 23rd Investor Program 2 Consumer Reports Poll 3A 43 25 of Americans Say Theyre on the Fence about Swine Flu Vaccine 58595 1 Consumer Reports Poll 3A 43 25 of Americans Say Theyre on the Fence about Swine Flu Vaccine 58595 2 Consumer Reports Poll 3A 43 25 of Americans Say Theyre on the Fence about Swine Flu Vaccine 58595 3 Consumer Reports Poll 3A 43 25 of Americans Say Theyre on the Fence about Swine Flu Vaccine 58595 4 Commercial Insurance Buyers Benefit From Ample Capacity 14306 1 Commercial Insurance Buyers Benefit From Ample Capacity 14306 2 Commercial Insurance Buyers Benefit From Ample Capacity 14306 3 Cardiac stem cell trial seeks to treat some heart attack patients 58592 1 Cardiac stem cell trial seeks to treat some heart attack patients 58592 2 Cardiac stem cell trial seeks to treat some heart attack patients 58592 3

[0] Covance to Present at Piper Jaffray 21st Annual Health Care Conference [0] Stipkala LLC to Sponsor SEBIO 2009 [0] Henry Schein to Present at the NASDAQ OMX 23rd Investor Program

...f $81.4 Million, RICHMOND, Calif., Feb. 5 Sangam... 2007 fourth quarter and year-end,financial result...2008., For the fourth quarter ended December 31, ...$6.7 million, or $0.17 per share, compared to a,ne...e same period in 2006.,As of December 31, 2007, th...

...ng innovative therapeutics for sickle cell anemia ...ogression, such as the important role,of hydration...ublished,online in Blood, the official journal of ...molecule therapy called senicapoc showed efficacy,...creasing hemoglobin,levels in patients with sickle...

Other Medicine Technology:Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results 2 Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results 3 Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results 4 Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results 5 Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results 6 Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results 7 Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results 8 Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells 2 Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells 3

Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells

(Date:12/1/2009)...Dec. 1 To date, hospitals have not... them for the $20 cost of the disposable sensor fo.... ,, Anesthesiologists have not told hospitals ...dementia from routine anesthesia over-medication. ...over-medication, message from their leaders becaus...

(Date:12/1/2009)...RNewswire-FirstCall/ -- Cell Therapeutics, Inc. (C...on at the 21st Annual Piper Jaffray Health Care Co...ern Time will be webcast live at www.celltherapeu...e in Holmes 1 at the New York Palace Hotel, and wi...tion. , , Piper Jaffray Heal...

(Date:12/1/2009)... the annual meeting of the Radiological Society of...y accurate means of identifying placenta accreta, ...mmon condition that is the leading cause of death ... "Due to the increase in cesarean sections and oth...ll, coupled with women giving birth later in life,...

(Date:12/1/2009)...ontrolled clinical trial presented today at the an...America (RSNA) reveal that one in five patients wi...lood to the legs and other parts of the body also ...e. , Peripheral arterial disease (PAD) occurs w...other substances, builds up in the arteries, limit...

(Date:12/1/2009)...viation-related injuries and deaths in the U.S. fi...U.S. hospitals with aviation-related injuries annu.... The study, conducted by researchers from the Joh...ter for Injury Research and Policy and Columbia Un... of patients were occupants of civilian, noncommer...

Breaking Medicine News(10 mins):Health News:5 Shocking Reasons Your Brain Isn't Worth Twenty Bucks Exposed 2 Health News:MRI helps detect life-threatening pregnancy complication 2 Health News:Severe asymptomatic heart disease may accompany narrowing in leg arteries 2 Health News:More than 1,000 patients in US admitted annually for aviation-related injuries 2

[0] 5 Shocking Reasons Your Brain Isn't Worth Twenty Bucks Exposed [0] Cell Therapeutics, Inc. (CTI) Piper Jaffray Presentation to be Webcast [0] MRI helps detect life-threatening pregnancy complication [0] Severe asymptomatic heart disease may accompany narrowing in leg arteries [0] More than 1,000 patients in US admitted annually for aviation-related injuries

...tion,Agency has announced that two Michigan asthma... Michigan in Grand Rapids and the University of,Mi...ee programs nationwide,to win EPA,s 2008 National ...e models for the rest of the country," said EPA,Re...

...r Improve in 86% at Six Months, TORONTO, May 9 /P....,(TSX: NDQ), a developer of real-time imaging and...oom, today announced that independent data was,pre...from two of the three European hospitals currently...

...lace an,employee can be as high as 2.41% of annual...n,s Service-Profit Chain is even higher. A benchma...effects of turnover on the,bottom line and offers ... from the report, a reduction in turnover,rates by...

...DRAXIS Health Inc. (TSX: DAX),(NASDAQ: DRAX ) rep...e,months ended March 31, 2008. Revenues and earnin...in the first quarter of 2007 as a result of lower,...,first quarter of 2007 of non-recurring items and ...

... 4,000 infection prevention and control profession...at a five-day conference next month to discuss man...y. , Strategies for infection prevention, best pr...ill be covered at the Association for Professional...

... the,history of Myanmar, the tropical Cyclone Narg...including its capital Yangon on Friday, May 2, 200...d and the death toll is,spiraling up, minute by mi...r area is about 24 million., Since there is no wa...

Two Michigan Asthma Management Programs Win EPA National Award Novadaq's OPTTX System Data Presented at ARVO Employee Engagement & Retention: Benchmarking Metrics and Networking Opportunity to Help Solve Today's Workforce Challenges DRAXIS Health Reports Results for the First Quarter of 2008 APIC conference to focus on patient safety and 'Targeting Zero' initiatives to reduce HAIs Myanmar Cyclone Relief Fund

Double LASIK Flap Irrigation Cannula

LASIK Irrigating Cannula

LASIK Flap Irrigator

Guiber CIS Se

Medicine Products:

Double LASIK Flap Irrigation Cannula LASIK Irrigating Cannula LASIK Flap Irrigator Guiber CIS Se

( dy of DMXAA (AS1404)combined with carb...)Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial,Health